P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
← catalyst calendarSponsored by ZyVersa Therapeutics, Inc. (industry) · ZVSA — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Withdrawn due to patient enrollment challenges
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-11 | actual | When the study began enrolling |
| Primary completion | 2026-08-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Kidney Disease
Intervention
- Drug: 2HPβCD — also filed as 2-hydroxypropyl-β-cyclodextrin
Primary outcomes
what the primary-completion date above is the date OFPercent change in 24-hour urinary albumin to creatinine ratio (UACR)
measured From Day 1 (baseline) to Week 12 (end of treatment)
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
measured 12 Weeks
Permalink · ZVSA's whole pipeline · Catalyst calendar · Every registered study · What changed